Results presented at ACC.24 showed that overall neutral results were due to directionally opposite effects in patients with reduced vs. preserved left ventricular ejection fraction Heart failure patients with reduced ejection (HFrEF) had 45% fewer adverse...
(Caesarea, Israel, March 28, 2024) –- V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a...
The RELIEVE-HF trial of the Ventura® Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure Caesarea, Israel. October 24, 2022: V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective,...
Echo Core Laboratory Data Demonstrates the Potential of a 5-mm Diameter Shunt to Reduce Filling Volumes and Enhance Systolic Function of Both Ventricles, Consistent with Reverse Cardiac Remodeling Madrid, Spain May 23, 2022 – V-Wave Ltd, manufacturer of the V-Wave...
Funds Support Completion of Pivotal Clinical Trial of V-Wave Implantable Interatrial Cardiac Shunt for Heart Failure Location: Caesarea, Israel and Agoura California V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive...
Seasoned Medical Device Executive Joins Breakthrough Structural Heart Company CAESAREA, ISRAEL AND AGOURA HILLS, CALIFORNIA – V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with...
Funds Support Further Development of V-Wave Implantable Interatrial Cardiac Shunt for Heart Failure and Pulmonary Hypertension CAESAREA, ISRAEL AND AGOURA HILLS, CALIFORNIA – V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive...
CE Mark for the Ventura™ Interatrial Shunt System is a significant milestone for V-Wave, as it recognizes that this therapeutic product conforms to the standards of the European Medical Device Directive V-Wave Ltd., a privately held medical device company developing...
CE Mark for the Ventura™ Interatrial Shunt System is a significant milestone for V-Wave, as it recognizes that this therapeutic product conforms to the standards of the European Medical Device Directive V-Wave Ltd., a privately held medical device company developing...
FDA Breakthrough Device Designation is granted to devices that have the potential to offer a “more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases.” V-Wave Ltd., a privately held medical device company developing novel...
Recent Comments